Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (September 2018)
21 slides from Viyash Scientific's shareholder meeting presentation, Sep 27, 2018
Slide 1: Warm Welcome to Shareholders
Warm Welcome to Shareholders 27th September 2018
Slide 2: Agenda
Agenda Strategic Performance Key Initiatives Agenda Decision and in FY18 for FY19 of AGM Actions 2 © 2018, SeQuent Scientific Limited, All Rights Reserved
Slide 3: Strategic Decision and Actions
Strategic Decision and Actions
Slide 4: Alivira emerges as India's Largest animal health company within 3 years of operations
Alivira emerges as India’s Largest animal health company within 3 years of operations 1 First Global pure-play Animal Health Company from India: API Business Demerger of Human Business completed Compliant and Efficient operations provides competitive advantage Stellar improvement in Annual performan
Slide 5: Creating India's largest Animal Health Company
Creating India’s largest Animal Health Company Revenue by Business Formulations Revenue by Geography Animal LATAM Health API 12% 25% Emerging 21% Markets 53% Europe 75% 14% Animal Health Turkey Formulation 5 © 2018, SeQuent Scientific Limited, All Rights Reserved
Slide 6: Formulations
Formulations Leading revenue 500+ 5 4 35+ Registrations Manufacturing State-of-art R&D driver Facilities R&D Centers Pipeline (4 EUGMP certified) 7.4X Sales growth in last 4 years 50%+ sales to regulated markets Innovative products catering to key therapeutic segments 1/3 products leverage in–house
Slide 7: APIs
APIs Scaling the 23 2 22 14+ Commercial Manufacturing Filings in R&D capability curve APIs Facilities US and EU Pipeline 3X Growth in sales to regulated markets in 4 years Margin expansion through focus on regulated markets New product strategy around patent expiry, innovation and market scarcity Le
Slide 8: R&D – Innovation to drive next phase
R&D – Innovation to drive next phase 60% 63% 1/3rd 35+ Products First Generics Portfolio Formulations leverage our and Niche comprising of under API-Integrated Products Injectables development Approach 8 © 2018, SeQuent Scientific Limited, All Rights Reserved
Slide 9: Performance in FY18
Sequent Proven Ability In Life Sciences More than Pharma Performance in FY18 ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 10: Financial Indicators
Financial Indicators All values in ₹ Mn Revenue from Operations EBITDA PAT 8,494 871 23.3% 50.6% 102 6,890 578 -139 FY17 FY18 FY17 FY18 FY17 FY18 10 © 2018, SeQuent Scientific Limited, All Rights Reserved
Slide 11: Relentless focus on execution
Relentless focus on execution All values in ₹ Mn Revenue Revenue 76.8% 16.2% 7.6% 16.2% 23.3% 2,090 2249 2328 8494 1942 1975 2,003 1,700 6,890 1,098 Q1 Q2 Q3 Q4 FY17 FY18 EBITDA EBITDA 140 440 50 206 190 bps bps bps bps bps 13.2% 9.6% 9.5% 10.0% 11.2% 7.6% 6.2% 5.2% 308 871 190 198 226 224 578 68 14
Slide 12: Consolidated Income Statement
Consolidated Income Statement All values in ₹ Mn FY18 Audited Particulars FY17 Audited Revenue from Operations 8,494 6,890 Material Consumption (4,625) (3,567) Gross Margin 3,870 3,323 % 45.6% 48.2% Operating Expenses (2,998) (2,745) EBITDA without Forex 871 578 % 10.3% 8.4% Exchange Gain / (Loss) (
Slide 13: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn Particulars 31-Mar-18 Net debt to EBITDA Net Debt to Equity ROCE Current ratio Shareholders' funds 6,476 0.38 2.34 Minority Interest 370 5.05 13.4% 0.27 Borrowings 3,046 2.97 8.3% Cash 598 2.02 Investments 2,217 Tangible Assets 2,269 Intangible Assets 2,671
Slide 14: Key Initiatives in FY19
Sequent Proven Ability In Life Sciences More than Pharma Key Initiatives +6). "4 +” Ge | &} In FY19 ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 15: Q1 FY19 performance
Q1 FY19 performance All values in ₹ Mn Sales Movement EBITDA Movement 21.1% 2,352 250 70.0% 1,942 147 Q1FY18 Q1FY19 Q1FY18 Q1FY19 15 © 2018, SeQuent Scientific Limited, All Rights Reserved
Slide 16: Post balance sheet date events
Post balance sheet date events Bremer - Strategic ▪ Establish Bremer as an injectable site for Regulated Markets (EU & USA) execution on track ▪ Business in emerging market to drive breakeven by Q4’19 Turkish manufacturing unit ▪ With this approval, Alivira now has 4 EU GMP certified formulations ma
Slide 17: Acquired EU-GMP API facility at Mahad
Acquired EU-GMP API facility at Mahad Complements our current manufacturing at Vizag (USFDA approved) and Tarapur (Intermediates) ▪ Comprehensive API manufacturing facility spread over 6 acres of land with 23 reactors having cumulative capacity of 76KL. ▪ Site is approved by EU authorities and also
Slide 18: FY19 Drivers
FY19 Drivers APIs Formulations Global Market Strategy ▪ API business to ▪ Maintain above ▪ Focus on uncrowded accelerate, driven by industry growth niche opportunities commercialisation in across geographies ▪ Grow relevant US ▪ Bremer to achieve capabilities to ▪ Increasing penetration breakeven by
Slide 19: Agenda for AGM
Sequent Proven Ability In Life Sciences More than Pharma Agenda for lp AGM ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 20: Agenda for AGM
Agenda for AGM Adoption of Financial statements for the period 1 ended 31 March 2018 Ordinary 2 Confirmation of Interim Dividend Business 3 Appointment of Director in place of retiring director Remuneration to the cost auditor for the 4 Financial Year 2018-19 Special Continuation of Dr. Gopakumar Na
Slide 21: Thank You
Sequent Proven Ability In Life Sciences ALIVIRA Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685 Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tel No: +91 22 4111 4777 | Website: www.sequent.in | E
SeQuent Scientific — Shareholder Meeting (September 2018) on 6ix